Nkarta (NKTX) EBIT Margin (2019)
Nkarta's (NKTX) quarterly EBIT Margin came in at 1534805.19% in Q3 2019, up 858.4% quarter-over-quarter from 202375.3% in Q2 2019.
Nkarta (NKTX) EBIT Margin (2019) Analysis & Trends
Nkarta's EBIT Margin history runs 1 years deep, the most recent figure standing at 1534805.19% for Q3 2019.
- On a quarterly basis, EBIT Margin changed N/A year-over-year to 1534805.19% in Q3 2019; TTM through Dec 2020 was 13378441.56%, a N/A change from a year earlier, with the FY2019 full-year figure at 19433.91%, changed N/A from the prior year.
- EBIT Margin improved to 1534805.19% in Q3 2019 per NKTX's latest filing, from 202375.3% in the prior quarter.
- Across five years, EBIT Margin topped out at 1534805.19% in Q3 2019 and bottomed at 202375.3% in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Nkarta | 170.79 Mn | 170.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 1,534,805.19% |
| Jun 30, 2019 | -202,375.30% |